| Literature DB >> 31536552 |
Hetani Ngobeni1,2, Stefano Tempia3,4,5,6, Adam L Cohen4,7, Sibongile Walaza3, Lazarus Kuonza1,2,8, Alfred Musekiwa2, Anne von Gottberg3,9, Orienka Hellferscee3, Nicole Wolter3,9, Florette K Treurnicht3, Jocelyn Moyes3,8, Fathima Naby3, Omphile Mekgoe3, Cheryl Cohen3,8.
Abstract
In 2014, the World Health Organization (WHO) proposed a new severe influenza surveillance case definition, which has not been evaluated in a high human immunodeficiency virus (HIV) prevalence setting. Our study aimed to assess the performance of this proposed case definition in identifying influenza among HIV-uninfected and HIV-infected children aged <5 years in South Africa. We prospectively enrolled children aged <5 years hospitalised with physician-diagnosed lower respiratory tract infection (LRTI) at two surveillance sites from January 2011 to December 2015. Epidemiologic and clinical data were collected. We tested nasopharyngeal aspirates for influenza using reverse transcription polymerase chain reaction. We used logistic regression to assess factors associated with influenza positivity among HIV-infected and HIV-uninfected children. We calculated sensitivity and specificity for different signs and symptoms and combinations of these for laboratory-confirmed influenza. We enrolled 2,582 children <5 years of age with LRTI of whom 87% (2,257) had influenza and HIV results, of these 14% (318) were HIV-infected. The influenza detection rate was 5% (104/1,939) in HIV-uninfected and 5% (16/318) in HIV-infected children. Children with measured fever (≥38°C) were two times more likely to test positive for influenza than those without measured fever among the HIV-uninfected (OR 2.2, 95% Confidence Interval (CI) 1.5-3.4; p<0.001). No significant association was observed between fever and influenza infection among HIV-infected children. Cough alone had sensitivity of 95% (95% CI 89-98%) in HIV-uninfected and of 100% (95% CI 79-100%) in HIV-infected children but low specificity: 7% (95% CI 6-8%) and 6% (95% CI 3-9%) in HIV-uninfected and HIV-infected children, respectively. The WHO post-2014 case definition for severe acute respiratory illness (SARI-an acute respiratory infection with history of fever or measured fever of ≥ 38°C and cough; with onset within the last ten days and requires hospitalization), had a sensitivity of 66% (95% CI 56-76%) and specificity of 46% (95% CI 44-48%) among HIV-uninfected and a sensitivity of 63% (95% CI 35-84%) and a specificity of 42% (95% CI 36-48%) among HIV-infected children. The sensitivity and specificity of the WHO post-2014 case definition for SARI were similar among HIV-uninfected and HIV-infected children. Our findings support the adoption of the 2014 WHO case definition for children aged <5 years irrespective of HIV infection status.Entities:
Year: 2019 PMID: 31536552 PMCID: PMC6752836 DOI: 10.1371/journal.pone.0222294
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
WHO surveillance case definitions evaluated.
| Case definition | Criteria |
|---|---|
| WHO before 2011 | Any child aged 2 months to 5 years with cough or difficulty in breathing |
| WHO 2014 (official) | An acute respiratory infection with history of fever or measured fever of ≥ 38°C and cough; with onset within the last ten days and requires hospitalization [ |
| WHO 2014 (with fever of ≥ 38°C and cough only) | An acute respiratory infection with measured fever of ≥ 38°C and cough; with onset within the last ten days and requires hospitalization. |
Fig 1Flow diagram showing cohort of children aged < 5years, South Africa, January 2011 to December 2015.
Epidemiological and clinical characteristics of HIV-infected and HIV-uninfected children aged <5 years testing influenza positive and hospitalised with severe respiratory illness at the Edendale and Klerksdorp hospitals, South Africa, 2011–2015.
| All patients | HIV-infected | HIV-uninfected | Unadjusted | |||
|---|---|---|---|---|---|---|
| Characteristic | p-value | |||||
| n/N (%) | n/N (%) | n/N (%) | OR (95% CI | |||
| <1 | 57/120 (48) | 6/16 (38) | 51/104 (49) | Reference | ||
| 1–4 | 63/120 (53) | 10/16 (63) | 53/104 (51) | 1.6 (0.5–5.7) | 0.39 | |
| Male | 73/120 (61) | 9/16 (57) | 64/104 (62) | 1.2 (0.4–3.0) | 0.69 | |
| Black | 114/115 (99) | 16/16 (100) | 98/99 (99) | 6 (0–241) | 1 | |
| 2011 | 33/120 (28) | 7 /16 (43) | 26/104 (25) | Reference | ||
| 2012 | 30/120 (25) | 3/16 (19) | 27/104 (26) | 0.4 (0.1–2.1) | 0.22 | |
| 2013 | 36/120 (30) | 4/16 (25) | 27/104 (31) | 0.6 (0.1–2.5) | 0.38 | |
| 2014 | 20/120 (17) | 2/16 (13) | 32/104 (17) | 0.2 (0.1–1.4) | 0.30 | |
| 2015 | 1/120 (1) | 0/16 (0) | 1/104 (1) | Empty | ||
| KTHC | 51/120 (43) | 10/16 (62) | 41/104 (39) | 2.6 (0.9–7.8) | 0.09 | |
| Any fever | 87/120 (73) | 10/16 (63) | 77/104 (74) | 0.6 (0.2–1.8) | 0.34 | |
| Fever ≥38 | 63/120 (53) | 7/16 (44) | 56/104 (54) | 0.7 (0.2–1.9) | 0.45 | |
| Cough | 114/119 (96) | 16/16 (100) | 98/103 (95) | 1 (0.1–inf) | 0.95 | |
| Difficulty breathing | 73/119 (61) | 9/16 (56) | 64/103 (62) | 0.8 (0.3–2.3) | 0.65 | |
| Diarrhoea | 25/119 (21) | 6/16 (38) | 19/103 (18) | 2.7 (0.9–8.2) | 0.09 | |
| Vomiting | 9/119 (8) | 3/16 (19) | 6/103 (6) | 3.7 (0.8–17) | 0.08 | |
| Inability to feed | 21/119 (18) | 2/16 (13) | 19/103 (18) | 0.6 (0.1–3.0) | 0.56 | |
| Lethargy | 49/119 (41) | 7/16 (44) | 42/103 (41) | 1.1 (0.4–3.2) | 0.82 | |
| Convulsions | 10/119 (8) | 1/16 (6) | 9/103 (9) | 0.7 (0.08–5.9) | 0.74 | |
| Stridor | 21/119 (18) | 4/16 (25) | 17/103 (17) | 1.7 (0.5–5.9) | 0.41 | |
| Ventilation | 61/118 (52) | 8/16 (50) | 53/102 (52) | 0.9 (0.3–2.7) | 0.88 | |
| Death | 1/118 (0.8) | 0/16 (0) | 1/102 (1) | 6 (0–249) | 1.00 | |
*CI: Confidence Interval.
Factors associated with influenza virus positivity among HIV-uninfected and HIV-infected children aged <5 years hospitalised with severe respiratory illness at the Edendale and Klerksdorp hospitals, South Africa, 2011–2015.
| HIV-uninfected | HIV-infected | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Symptom | Influenza positive n/N (%) | Unadjusted OR (95%CI | p-value | Adjusted OR (95%CI | p-value | Influenza positive n/N (%) | Unadjusted OR (95%CI | p-value | |
| N | 48/1 260 (4) | Ref | 9/176 (5) | Ref | |||||
| Y | 56/679 (8) | 2.3 (1.5–3.4) | <0.001 | 2.2 (1.5–3.4) | <0.001 | 7/142(5) | 0.9 (0.3–2.7) | 0.94 | |
| N | 27/738 (4) | Ref | 6/102 (6) | Ref | |||||
| Y | 77/1 194 (6) | 1.8 (1.1–2.8) | 0.007 | 10/212 (5) | 0.8 (0.2–2.2) | 0.66 | |||
| N | 5/136 (4) | Ref | 0/17 (0) | Ref | |||||
| Y | 98/1 795 (5) | 1.5 (0.6–3.7) | 0.37 | 16/300 (5) | 1.3 (0.2– +inf) | 0.80 | |||
| ≤7 | 88/1 754 (5) | Ref | 12/264 (5) | Ref | |||||
| 8–10 | 3/ 32 (9) | 2 (0.5–6.5) | 0.26 | 1/7 (14) | 3.5 (0.3–31.4) | 0.26 | |||
| 11–14 | 2/ 26 (8) | 1.6 (0.3–6.7) | 0.54 | 1/10 (10) | 2.3 (0.2–20) | 0.43 | |||
| 15+ | 5/ 66 (8) | 1.6 (0.6–3.9) | 0.36 | 2/21 (10) | 2.2 (0.4–11) | 0.32 | |||
| N | 97/1 844 (5) | Ref | 13/295 (4) | Ref | |||||
| Y | 6/87 (7) | 1.3 (0.6–3.1) | 0.50 | 3/22 (13) | 3.4 (0.9–13) | 0.07 | |||
| N | 84/1 671 (5) | Ref | 10/245 (4) | Ref | |||||
| Y | 19/260 (7) | 1.5 (0.9–2.5) | 0.13 | 6/72 (8) | 2.1 (0.7–6) | 0.15 | |||
| N | Ref | 14/270 (5) | Ref | ||||||
| Y | 19/295 (6) | 1.3 (0.8–2.1) | 0.36 | 2/47 (4) | 0.8 (0.1–3.7) | 0.79 | |||
| N | 61/1 098 (6) | Ref | 9/156 (6) | Ref | |||||
| Y | 42/832 (5) | 0.9 (0.6–1.4) | 0.62 | 7/161 (4) | 0.7 (0.3–2.0) | 0.57 | |||
| N | 94/1 856 (5) | Ref | 15/311 (5) | Ref | |||||
| Y | 9/75 (12) | 2.6 (1.2–5.3) | 0.02 | 1/6 (17) | 4 (0.4–36) | 0.22 | |||
| N | 86/1 426 (6) | Ref | 12/242 (5) | Ref | |||||
| Y | 17/505 (3) | 0.5 (0.3–0.9) | 0.02 | 4/75 (3) | 0.1 (0.03–3.4) | 0.90 | |||
| N | Ref | 7/109 (10) | Ref | ||||||
| Y | 64/1 320 (4) | 0.7 (0.5–1.1) | 0.17 | 9/208 (4) | 0.7 (0.2–1.8) | 0.42 | |||
| Eden | 63/1 272 (5) | Ref | 6/167 (4) | Ref | |||||
| KTHC | 41/667 (6) | 1.3 (0.8–1.9) | 0.26 | 1.7 (0.9–1.3) | 0.54 | 10/151 (7) | 1.9 (0.7–5.4) | 0.22 | |
*CI: Confidence Interval
Hosmer-Lemeshow Goodness-of-fit-test for the multivariable model among HIV-uninfected children, fever (> = = 38°C) & site: p-value 0.91.
Sensitivity, specificity and predictive values of signs and symptoms for influenza virus positivity among HIV-infected and HIV-uninfected children aged <5 years hospitalised with severe respiratory illness at the Edendale and Klerksdorp hospitals, South Africa, 2011–2015.
| Factors | Influenza positivity | Sensitivity | Specificity | PPV | NPV | |
|---|---|---|---|---|---|---|
| Presence of factor | Absence of factor | |||||
| Fever >38°C | 63/821 (8) | 57/1 436 (3) | 53 (43–62) | 64 (62–67) | 8 (6–10) | 96 (94–97) |
| Any fever | 87/1 406 (6) | 33/840 (4) | 73 (63–80) | 38 (36–40) | 6 (5–8) | 96 (95–97) |
| Cough | 114/2 095 (5) | 5/153 (3) | 96 (91–99) | 7 (6–9) | 5 (5–7) | 97 (93–99) |
| Difficulty breathing | 73/1 528 (5) | 46/721 (6) | 61 (52–70) | 32 (28–34) | 5 (4–6) | 94 (92–95) |
| Diarrhoea | 25/332 (8) | 94/1 916 (5) | 21 (14–30) | 86 (84–87) | 8 (5–11) | 95 (94–96) |
| Vomiting | 9/109 (8) | 110/2 139 (5) | 8 (4–14) | 95 (94–96) | 8 (3–15) | 95 (94–96) |
| No feeding | 21/342 (6) | 98/1 907 (5) | 18 (11–26) | 85 (83–86) | 6 (3–8) | 94 (93–96) |
| Lethargy | 49/993 (5) | 70/1 254 (6) | 41 (32–51) | 56 (53–58) | 5 (3–7) | 94 (93–96) |
| Convulsion | 10/81 (12) | 109/2 167 (5) | 8 (4–12) | 97 (96–98) | 12 (6–22) | 95 (94–96) |
| Stridor | 21/580 (4) | 98/1 668 (6) | 18 (11–26) | 74 (71–76) | 4 (2–6) | 94 (93–95) |
| ≤7 days | 14/162 (9) | 100/2 018 (5) | 91 (86–95) | 5 (4–6) | 7 (6–8) | 88 (82–93) |
| ≤10 days | 10/123 (8) | 104/2 057 (5) | 92 (86–96) | 5 (4–6) | 6 (5–7) | 91 (85–96) |
| ≤14 days | 7/87 (8) | 107/2 093 (5) | 92 (84–97) | 5 (4–6) | 4 (3–5) | 94 (88–96) |
| ≤7 days | 100 | 100 | 88 | |||
| ≤10 days | 4 | 104 | 91 | |||
| ≤14 days | 3 | 107 | 94 | |||
| 15+ days | 7 | 114 | 100 | |||
*PPV: positive predictive value.
**NPV: negative predictive value.
Sensitivity, specificity and predictive values of signs and symptoms for influenza virus positivity among HIV-uninfected and HIV-infected children aged <5 years hospitalised with severe respiratory illness at the Edendale and Klerksdorp hospitals, South Africa, 2011–2015.
| Value (%) and 95% Confidence Interval | ||||||||
|---|---|---|---|---|---|---|---|---|
| HIV uninfected | HIV infected | |||||||
| 54 (43–64) | 66 (64–68) | 8 (6–10) | 96 (95–97) | 44 (20–70) | 55 (50–61) | 5 (2–10) | 95 (91–98) | |
| 74 (64–82) | 39 (37–41) | 6 (5–8) | 96 (95–98) | 63 (27–85) | 32 (27–39) | 5 (2–9) | 194 (88–98) | |
| 95 (89–98) | 7 (6–8) | 6 (5–7) | 96 (92–99) | 100 (79–100) | 6 (3–9) | 5 (3–9) | 100 (80–100) | |
| 62 (52–72) | 31 (29–33) | 5 (4–6) | 94 (91–95) | 56 (30–80) | 34 (29–40) | 4 (2–8) | 94 (87–97) | |
| 18 (11–27) | 87 (85–88) | 7 (5–11) | 95 (94–96) | 38 (15–65) | 78 (73–83) | 8 (3–17) | 96 (93–98) | |
| 6 (2–12) | 96 (95–97) | 7 (3–11) | 95 (94–96) | 19 (4–47) | 94 (90–96) | 14 (3–35) | 96 (93–98) | |
| 18 (12–27) | 85 (83–87) | 6 (4–10) | 95 (94–96) | 13 (2–38) | 85 (81–89) | 4 (1–15) | 95 (92–97) | |
| 41 (31–51) | 57 (55–60) | 5 (4–7) | 94 (93–96) | 44 (20–70) | 49 (43–55) | 4 (2–9) | 94 (89–97) | |
| 9 (4–16) | 96 (95–97) | 12 (6–22) | 95 (94–96) | 6 (0.2–30) | 98 (96–100) | 17 (0.4–64) | 95 (92–97) | |
| 17 (10–25) | 73 (71–75) | 3 (2–6) | 93 (94–95) | 25 (7–52) | 76 (71–81) | 5 (2–13) | 95 (92–97) | |
| ≤ | 92 (86–96) | 5 (4–6) | 6 (5–8) | 90 (82–95) | 90 (75–97) | 6 (3–8) | 12 (8–16) | 75 (48–93) |
| ≤ | 92 (85–97) | 5 (4–6) | 5 (4–6) | 93 (86–97) | 90 (74–98) | 5 (3–8) | 10 (7–14) | 81 (54–96) |
| ≤ | 92 (83–98) | 5 (4–6) | 3 (3–4) | 95 (89–98) | 91 (69–99) | 5 (3–8) | 7 (4–10) | 88 (62–98) |
*PPV: positive predictive value
**NPV: negative predictive value
Sensitivity, specificity and predictive values of various case definitions for influenza virus positivity among HIV-uninfected and HIV-infected children aged <5 years hospitalised with severe respiratory illness at the Edendale and Klerksdorp hospitals, South Africa, 2011–2015.
| Value (%) and 95% Confidence Interval | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV-uninfected | HIV-infected | All | ||||||||||
| Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | |
| 2011WHO | 66 (56–76) | 32 (29–34) | 6 (5–7) | 94 (91–96) | 63 (35–85) | 31 (26–37) | 5 (2–9) | 94 (87–98) | 66 (56–74) | 32 (30–34) | 6 (5–7) | 94 (91–96) |
| 2014WHO | 66 (56–76) | 46 (44–48) | 6 (5–8) | 96 (95–97) | 63 (35–84) | 42 (36–48) | 6 (3–10) | 95 (90–98) | 66 (56–74) | 45 (43–47) | 6 (5–8) | 96 (95–97) |
| 2014WHO (fever≥38) | 48 (38–58) | 70 (68–73) | 8 (6–11) | 96 (95–97) | 44 (20–70) | 61 (55–67) | 6 (2–12) | 95 (91–98) | 47 (38–57) | 69 (67–71) | 8 (6–10) | 96 (95–97) |
*PPV: positive predictive value.
**NPV: negative predictive value
#Documented fever and cough.